Drug Profile

Vemzatatug vedotin - AstraZeneca

Alternative Names: AZD-0305

Latest Information Update: 11 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AstraZeneca
Class Antibodies; Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates
Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

15 Jan 2025 Phase-I/II clinical trials in Multiple myeloma (Second-line therapy or greater) in Australia, Canada, China, France, Germany, Japan, Spain (IV) (NCT06106945)
05 Dec 2023 Phase-I/II clinical trials in Multiple myeloma (Second-line therapy or greater) in USA (IV) (NCT06106945)
30 Oct 2023 Preclinical trials in Multiple myeloma in United Kingdom (IV) (NCT06106945)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com